bentamapimod   Click here for help

GtoPdb Ligand ID: 9926

Synonyms: AS-602801 | AS602801 | PGL-5001 | PGL5001
Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: Bentamapimod (a.k.a. PGL-5001 and AS602801) is novel and orally active Jun kinase inhibitor (JNK1= MAPK8 and JNK2= MAPK9). It has shown preclinical efficacy that may be applied to the treatment of endometriotic lesions [1,3]. It also inhibits cancer stem cells in vitro and in vivo [2]. It was originally developed by Merck Seroneo (JNK-I AS602801) and then in-licensed by PregLem and re-named PGL5001 (PGL5 may also be used).
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 6
Hydrogen bond donors 0
Rotatable bonds 7
Topological polar surface area 112.4
Molecular weight 457.16
XLogP 2.27
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES N#CC(c1nc2c(s1)cccc2)c1ccnc(n1)OCc1ccc(cc1)CN1CCOCC1
Isomeric SMILES N#CC(c1nc2c(s1)cccc2)c1ccnc(n1)OCc1ccc(cc1)CN1CCOCC1
InChI InChI=1S/C25H23N5O2S/c26-15-20(24-28-22-3-1-2-4-23(22)33-24)21-9-10-27-25(29-21)32-17-19-7-5-18(6-8-19)16-30-11-13-31-14-12-30/h1-10,20H,11-14,16-17H2
InChI Key XCPPIJCBCWUBNT-UHFFFAOYSA-N
Bioactivity Comments
Bentamapimod is likely one of the compounds claimed in Merck Serono's patent US20130267512A1, as the SMILES string returns this patent via a SureChEMBL open patent search. No potency data is provided in the patent for the direct inhibition of the JNK kinases, so we are unable to validate the compound's primary molecular target, pending publication in peer reviewed literature.